Telix Pharmaceuticals (TLX) Share Forecast & Price Target

Compare

496 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TLX Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Telix

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TLX Stock 12 Month Forecast

Average Price Target

AU$26.94

▲(129.71% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is AU$26.94 with a high forecast of AU$35.06 and a low forecast of AU$17.03. The average price target represents a 129.71% change from the last price of AU$11.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"AU$13","36":"AU$36","18.75":"AU$18.75","24.5":"AU$24.5","30.25":"AU$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.055505745596,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$35.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.9447738752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$26.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.0269599335752,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$17.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18.75,24.5,30.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.05,16.58888505735354,18.127770114707076,19.666655172060615,21.205540229414154,22.744425286767694,24.283310344121233,25.82219540147477,27.361080458828308,28.899965516181847,30.438850573535383,31.977735630888922,33.51662068824246,{"y":35.055505745596,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.05,15.964982605784616,16.879965211569232,17.794947817353847,18.709930423138463,19.62491302892308,20.53989563470769,21.454878240492306,22.36986084627692,23.284843452061537,24.199826057846153,25.114808663630768,26.029791269415384,{"y":26.9447738752,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.05,15.202073841044246,15.354147682088493,15.506221523132739,15.658295364176984,15.810369205221232,15.962443046265477,16.114516887309723,16.266590728353968,16.418664569398214,16.570738410442463,16.722812251486708,16.874886092530954,{"y":17.0269599335752,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetAU$35.06

Average Price TargetAU$26.94

Lowest Price TargetAU$17.03

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Laura Sutcliffe

Citi

AU$34

Buy

189.86%

Upside

Reiterated

12/17/25

Citi Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Craig Wong-Pan

RBC Capital

AU$17

Hold

44.93%

Upside

Initiated

12/14/25

Telix Pharmaceuticals (TLPPF) Gets a Hold from RBC Capital

Shane Storey

Canaccord Genuity

AU$27.41→AU$28.5

Buy

142.97%

Upside

Reiterated

12/08/25

Telix Pharmaceuticals (TLPPF) Receives a Buy from Canaccord Genuity

David Bailey

Morgan Stanley

AU$25.4

Buy

116.54%

Upside

Reiterated

11/20/25

Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley

John Hester

Bell Potter

AU$23

Buy

96.08%

Upside

Reiterated

10/22/25

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

AU$28.13→AU$28.06

Buy

139.22%

Upside

Reiterated

10/16/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)

Tara Bancroft

TD Cowen

AU$35

Buy

198.38%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals: Strong Q3 Performance and Strategic Positioning Reinforce Buy Rating

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

AU$22.6

Buy

92.67%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

David Stanton

Jefferies

AU$26.7→AU$27.1

Buy

131.03%

Upside

Reiterated

10/14/25

Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

David Dai

UBS

AU$31

Buy

164.28%

Upside

Reiterated

10/14/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS

Andrew Paine

CLSA

AU$24.25

Buy

106.73%

Upside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

David Low

J.P. Morgan

AU$26.25→AU$16.5

Hold

40.66%

Upside

Downgraded

08/31/25

J.P. Morgan downgrades Telix Pharmaceuticals (TLPPF) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Laura Sutcliffe

Citi

AU$34

Buy

189.86%

Upside

Reiterated

12/17/25

Citi Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Craig Wong-Pan

RBC Capital

AU$17

Hold

44.93%

Upside

Initiated

12/14/25

Telix Pharmaceuticals (TLPPF) Gets a Hold from RBC Capital

Shane Storey

Canaccord Genuity

AU$27.41→AU$28.5

Buy

142.97%

Upside

Reiterated

12/08/25

Telix Pharmaceuticals (TLPPF) Receives a Buy from Canaccord Genuity

David Bailey

Morgan Stanley

AU$25.4

Buy

116.54%

Upside

Reiterated

11/20/25

Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley

John Hester

Bell Potter

AU$23

Buy

96.08%

Upside

Reiterated

10/22/25

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Steven Wheen

Jarden

AU$28.13→AU$28.06

Buy

139.22%

Upside

Reiterated

10/16/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Telix Pharmaceuticals (Other OTC: TLPPF) and Geron (NASDAQ: GERN)

Tara Bancroft

TD Cowen

AU$35

Buy

198.38%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals: Strong Q3 Performance and Strategic Positioning Reinforce Buy Rating

Unknown Analyst

Ord Minnett

Not Ranked

Ord Minnett

AU$22.6

Buy

92.67%

Upside

Reiterated

10/15/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett

David Stanton

Jefferies

AU$26.7→AU$27.1

Buy

131.03%

Upside

Reiterated

10/14/25

Jefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

David Dai

UBS

AU$31

Buy

164.28%

Upside

Reiterated

10/14/25

Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS

Andrew Paine

CLSA

AU$24.25

Buy

106.73%

Upside

Reiterated

10/03/25

CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

David Low

J.P. Morgan

AU$26.25→AU$16.5

Hold

40.66%

Upside

Downgraded

08/31/25

J.P. Morgan downgrades Telix Pharmaceuticals (TLPPF) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

1 Month

xxx

Success Rate

11/16 ratings generated profit

Average Return

+6.98%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 68.75% of your transactions generating a profit, with an average return of +6.98% per trade.

3 Months

xxx

Success Rate

12/16 ratings generated profit

Average Return

+25.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +25.54% per trade.

1 Year

Steven WheenJarden

Success Rate

16/22 ratings generated profit

Average Return

+49.16%

reiterated a buy rating 2 months ago

Copying Steven Wheen's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +49.16% per trade.

2 Years

xxx

Success Rate

13/22 ratings generated profit

Average Return

+93.78%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +93.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TLX has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. TLX average Analyst price target in the past 3 months is 26.94.

Each month's total comprises the sum of three months' worth of ratings.

TLX Financial Forecast

TLX Earnings Forecast

Next quarter’s earnings estimate for TLX is AU$0.08 with a range of AU$0.08 to AU$0.08. The previous quarter’s EPS was AU$0.02. TLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.

TLX Sales Forecast

Next quarter’s sales forecast for TLX is AU$326.32M with a range of AU$321.20M to AU$336.28M. The previous quarter’s sales results were AU$615.34M. TLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.

TLX Stock Forecast FAQ

What is AU:TLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 26.94.

What is AU:TLX’s upside potential, based on the analysts’ average price target?

Telix Pharmaceuticals Ltd. has 129.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?

Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Telix Pharmaceuticals Ltd.’s share price target?

The average share price target for Telix Pharmaceuticals Ltd. is 26.94. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is AU$35.06 ,and the lowest forecast is AU$17.03. The average share price target represents 129.71% Increase from the current price of AU$11.73.

What do analysts say about Telix Pharmaceuticals Ltd.?

Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Telix Pharmaceuticals Ltd.?

To buy shares of AU:TLX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Telix Pharmaceuticals (TLX) Share Forecast & Price Target

TLX Analyst Ratings

TLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Telix Pharmaceuticals

TLX Analyst Recommendation Trends

TLX Financial Forecast

TLX Earnings Forecast

TLX Sales Forecast

TLX Stock Forecast FAQ

Detailed List of Analyst Forecasts